Key clinical point: Most patients with psoriatic arthritis (PsA) experienced mildly severe psoriasis, but it had an impact on their health-related quality of life (HRQoL) when assessed using a dermatology-specific HRQoL questionnaire (Skindex-17).

Major finding: The majority of patients (71%) had mild psoriasis and remained in this category at 12 months of follow-up. Psoriasis severity did not fluctuate much during the first year with the proportion of patients without psoriasis increasing from 17% at baseline to 34% and those with severe psoriasis remaining stable with 3% at baseline and 2% at 12 months. Psoriasis Area Severity Index score was significantly associated with a psychosocial subscale of Skindex-17 at baseline (incidence rate ratio [IRR], 1.05; 95% confidence interval [CI], 1.02-1.08) and 12 months (IRR, 1.10; 95% CI, 1.05-1.15).

Study details: Findings are from a Dutch cohort including 644 patients with newly diagnosed PsA who were followed up for 1 year.

Disclosures: The study received no specific funding. The authors declared no conflict of interests.

Source: Kasiem FR et al. Rheumatology. 2021 Jul 24. doi: 10.1093/rheumatology/keab606.

Key clinical point: Most patients with psoriatic arthritis (PsA) experienced mildly severe psoriasis, but it had an impact on their health-related quality of life (HRQoL) when assessed using a dermatology-specific HRQoL questionnaire (Skindex-17).

Major finding: The majority of patients (71%) had mild psoriasis and remained in this category at 12 months of follow-up. Psoriasis severity did not fluctuate much during the first year with the proportion of patients without psoriasis increasing from 17% at baseline to 34% and those with severe psoriasis remaining stable with 3% at baseline and 2% at 12 months. Psoriasis Area Severity Index score was significantly associated with a psychosocial subscale of Skindex-17 at baseline (incidence rate ratio [IRR], 1.05; 95% confidence interval [CI], 1.02-1.08) and 12 months (IRR, 1.10; 95% CI, 1.05-1.15).

Study details: Findings are from a Dutch cohort including 644 patients with newly diagnosed PsA who were followed up for 1 year.

Disclosures: The study received no specific funding. The authors declared no conflict of interests.

Source: Kasiem FR et al. Rheumatology. 2021 Jul 24. doi: 10.1093/rheumatology/keab606.

Key clinical point: Most patients with psoriatic arthritis (PsA) experienced mildly severe psoriasis, but it had an impact on their health-related quality of life (HRQoL) when assessed using a dermatology-specific HRQoL questionnaire (Skindex-17).

Major finding: The majority of patients (71%) had mild psoriasis and remained in this category at 12 months of follow-up. Psoriasis severity did not fluctuate much during the first year with the proportion of patients without psoriasis increasing from 17% at baseline to 34% and those with severe psoriasis remaining stable with 3% at baseline and 2% at 12 months. Psoriasis Area Severity Index score was significantly associated with a psychosocial subscale of Skindex-17 at baseline (incidence rate ratio [IRR], 1.05; 95% confidence interval [CI], 1.02-1.08) and 12 months (IRR, 1.10; 95% CI, 1.05-1.15).

Study details: Findings are from a Dutch cohort including 644 patients with newly diagnosed PsA who were followed up for 1 year.

Disclosures: The study received no specific funding. The authors declared no conflict of interests.

Source: Kasiem FR et al. Rheumatology. 2021 Jul 24. doi: 10.1093/rheumatology/keab606.

Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.

Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.

Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.

Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.

Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.

Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.

Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.

Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.

Key clinical point: Guselkumab 100 mg every 4 weeks (Q4W) or 8 weeks (Q8W) provided a clinically meaningful reduction in fatigue in patients with active psoriatic arthritis (PsA).

Major finding: At week 24, a higher proportion of patients receiving guselkumab Q4W (63%; P less than .001) and Q8W (54%; P less than .01) vs placebo (35%) achieved 4-point or higher improvement in Functional Assessment of Chronic Illness Therapy-Fatigue scores in DISCOVER-1. Findings were similar with guselkumab Q4W (60%; P less than .01) and Q8W (61%; P less than .001) vs placebo (46%) in DISCOVER-2. Improvements were maintained until week 52.

Study details: Findings are from the analysis of 2 phase 3 trials (DISCOVER 1 and DISCOVER 2) including 1,120 patients with active PsA who were randomly assigned to guselkumab 100 mg at week 0 and then Q4W, guselkumab 100 mg at weeks 0 and 4 and then Q8W, or placebo Q4W.

Disclosures: This study was funded by Janssen Research & Development, LLC. Some of the authors declared receiving grants, consulting fees, and speaker’s bureau support from various sources including Janssen. Seven of the authors declared being employees and stockholders of Johnson & Johnson.

Source: Rahman P et al. Arthritis Res Ther. 2021 Jul 14. doi: 10.1186/s13075-021-02554-3.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: Radiofrequency ablation was associated with improved survival in HCC patients with early and intermediate stage HCC.

Major finding: The survival in patients with liver cancer due to HCC was 82.3% at 12 months and 57.8% at 36 months for patients who received radiofrequency ablation.

Study details: The data come from a retrospective cohort study of 62 adults with HCC; of these, 32.3% were early stage, based on Barcelona-Clinic Liver Cancer staging system (BCLC) A, and 67.7% were intermediate, based on BCLC B. A total of 46 patients underwent radiofrequency ablation as their first-line treatment.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Sulaiman AS et al. J Gastrointest Cancer. 2021 Aug 11. doi: 10.1007/s12029-021-00676-0.

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: A treatment strategy of drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) showed similar rates of survival and adverse events in patients with HCC adjacent to the gallbladder

Major finding: At one month after treatment, complete response rate, objective response rate and disease control rate were 79.2%, 95.8% and 100.0% in the DEB-TACE plus MWA group. Rates of recurrence-free survival, progression-free survival, and overall survival were similar between the DEB-TACE plus MWA group and the standard surgery group.

Study details: The data come from 54 adults with HCC adjacent to the gallbladder. Of these, 24 patients underwent either drug-eluting beads-transarterial chemoembolization (DEB-TACE) plus microwave ablation (MWA) and 30 underwent standard surgery.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Cai L et al. Am J Transl Res. 2021 Jul 15. PMCID:  PMC8340149

Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.

Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).

Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).

Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.

Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.

Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.

Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).

Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).

Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.

Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.

Key clinical point: Both recurrence-free survival and overall survival were higher in cirrhotic HCC patients without macrovascular invasion who had tumors of 5 cm or less compared to those with larger tumors.

Major finding: The rates of 5-year recurrence-free survival and overall survival were higher in patients with tumors of 5 cm or less compared to those with tumors greater than 5 cm (38.3% vs 25.1% and 61.5% vs 59.9%, respectively).

Study details: The data come from a retrospective study of 813 cirrhotic adults with solitary HCC without macrovascular invasion who underwent curative hepatectomy between 2001 and 2014. Tumor size was categorized as 5 cm or less (464 patients) or greater than 5 cm (349 patients).

Disclosures: The study was supported by the Natural Science Foundation of Hubei Province of China and the National Science and Technology Major Project of China. The researchers had no financial conflicts to disclose.

Source: Liang B-Y et al. Sci Rep. 2021 Aug 11. doi: 10.1038/s41598-021-95835-5.

Key clinical point: Infectious complications during curative resection for HCC significantly reduced overall survival and recurrence-free survival; outcomes were even worse for patients with non-surgical site infections vs surgical site infections.

Major finding: A total of 269 patients experienced a postoperative complication. Overall survival was significantly shorter in HCC patients who experienced infectious complications after curative surgery compared to those who did not (46.5 months vs 106.4 months, P < 0.001).

Study details: The data come from 734 adults with hepatocellular carcinoma who underwent curative resection between 2000 and 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Wei T et al. Ann Surg Oncol. 2021 Aug 10. doi: 10.1245/s10434-021-10565-2.

Key clinical point: Infectious complications during curative resection for HCC significantly reduced overall survival and recurrence-free survival; outcomes were even worse for patients with non-surgical site infections vs surgical site infections.

Major finding: A total of 269 patients experienced a postoperative complication. Overall survival was significantly shorter in HCC patients who experienced infectious complications after curative surgery compared to those who did not (46.5 months vs 106.4 months, P < 0.001).

Study details: The data come from 734 adults with hepatocellular carcinoma who underwent curative resection between 2000 and 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Wei T et al. Ann Surg Oncol. 2021 Aug 10. doi: 10.1245/s10434-021-10565-2.

Key clinical point: Infectious complications during curative resection for HCC significantly reduced overall survival and recurrence-free survival; outcomes were even worse for patients with non-surgical site infections vs surgical site infections.

Major finding: A total of 269 patients experienced a postoperative complication. Overall survival was significantly shorter in HCC patients who experienced infectious complications after curative surgery compared to those who did not (46.5 months vs 106.4 months, P < 0.001).

Study details: The data come from 734 adults with hepatocellular carcinoma who underwent curative resection between 2000 and 2017.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Wei T et al. Ann Surg Oncol. 2021 Aug 10. doi: 10.1245/s10434-021-10565-2.

Key clinical point: Liver stiffness was a stronger predictor of symptomatic post-hepatectomy liver failure in HCC patients after major hepatectomy compared to CTP grade, and was significantly more effective for stratifying SPHLF risks in CTP grade A for both major and minor hepatectomy.

Major finding: Liver stiffness of 9.5 kPa or greater, as measured by measured by two-dimensional shear wave elastography, was superior to Child-Turcotte-Pugh (CTP) grade for predicting symptomatic post-hepatectomy liver failure after major hepatectomy (72.4% vs 18.9%), although CTP was more effective at predicting liver failure after minor hepatectomy (100% vs 12.2%).

Study details: The data come from a review of 119 adults with HCC who underwent hepatectomy between August 2018 and July 2019; all patients underwent preoperative assessments for liver stiffness.

Disclosures: The study was supported by the National Natural Science Foundation of China, the National Natural Science Foundation of Guangdong Province, and the State Key Project on Infectious Diseases of China. The researchers had no financial conflicts to disclose.

Source: Long H et al. Ann Surg Oncol. 2021 Aug 11. doi: 10.1245/s10434-021-10563-4.

Key clinical point: Liver stiffness was a stronger predictor of symptomatic post-hepatectomy liver failure in HCC patients after major hepatectomy compared to CTP grade, and was significantly more effective for stratifying SPHLF risks in CTP grade A for both major and minor hepatectomy.

Major finding: Liver stiffness of 9.5 kPa or greater, as measured by measured by two-dimensional shear wave elastography, was superior to Child-Turcotte-Pugh (CTP) grade for predicting symptomatic post-hepatectomy liver failure after major hepatectomy (72.4% vs 18.9%), although CTP was more effective at predicting liver failure after minor hepatectomy (100% vs 12.2%).

Study details: The data come from a review of 119 adults with HCC who underwent hepatectomy between August 2018 and July 2019; all patients underwent preoperative assessments for liver stiffness.

Disclosures: The study was supported by the National Natural Science Foundation of China, the National Natural Science Foundation of Guangdong Province, and the State Key Project on Infectious Diseases of China. The researchers had no financial conflicts to disclose.

Source: Long H et al. Ann Surg Oncol. 2021 Aug 11. doi: 10.1245/s10434-021-10563-4.

Key clinical point: Liver stiffness was a stronger predictor of symptomatic post-hepatectomy liver failure in HCC patients after major hepatectomy compared to CTP grade, and was significantly more effective for stratifying SPHLF risks in CTP grade A for both major and minor hepatectomy.

Major finding: Liver stiffness of 9.5 kPa or greater, as measured by measured by two-dimensional shear wave elastography, was superior to Child-Turcotte-Pugh (CTP) grade for predicting symptomatic post-hepatectomy liver failure after major hepatectomy (72.4% vs 18.9%), although CTP was more effective at predicting liver failure after minor hepatectomy (100% vs 12.2%).

Study details: The data come from a review of 119 adults with HCC who underwent hepatectomy between August 2018 and July 2019; all patients underwent preoperative assessments for liver stiffness.

Disclosures: The study was supported by the National Natural Science Foundation of China, the National Natural Science Foundation of Guangdong Province, and the State Key Project on Infectious Diseases of China. The researchers had no financial conflicts to disclose.

Source: Long H et al. Ann Surg Oncol. 2021 Aug 11. doi: 10.1245/s10434-021-10563-4.

Key clinical point: Nomograms for both recurrence-free survival and overall survival based on tumor clinical features, operative factors, liver function, and systemic inflammatory or immune status were effective predictors for stratifying SLH-HCC patients in low-, medium-, and high-risk groups.

Major finding: Nomograms for post-surgical recurrence-free survival and overall survival in patients with SLH-HCC achieved C-indexes of 0.85 and 0.86, respectively. The nomograms were based on diameter, differentiation, microvascular invasion, α-fetoprotein, preoperative transcatheter arterial chemoembolisation therapy, scope of liver resection and intraoperative blood transfusion, albumin-bilirubin grade, and neutrophil-to-lymphocyte ratio.

Study details: The data come from a retrospective study of 2,469 adult patients with single large and huge hepatocellular carcinoma (SLH-HCC) defined as greater than 5.0 cm in diameter who underwent curative resection between January 2005 and December 2015.

Disclosures: The study was supported by the National Science and Technology Major Project of China, the National Natural Science Foundation of China, and the Sun-Yat Sen University Clinical Research 5010 Program. The researchers had no financial conflicts to disclose.

Source: Wang J-C et al.  Eur J Cancer. 2021 Aug 6. doi: 10.1016/j.ejca.2021.07.009.

Key clinical point: Nomograms for both recurrence-free survival and overall survival based on tumor clinical features, operative factors, liver function, and systemic inflammatory or immune status were effective predictors for stratifying SLH-HCC patients in low-, medium-, and high-risk groups.

Major finding: Nomograms for post-surgical recurrence-free survival and overall survival in patients with SLH-HCC achieved C-indexes of 0.85 and 0.86, respectively. The nomograms were based on diameter, differentiation, microvascular invasion, α-fetoprotein, preoperative transcatheter arterial chemoembolisation therapy, scope of liver resection and intraoperative blood transfusion, albumin-bilirubin grade, and neutrophil-to-lymphocyte ratio.

Study details: The data come from a retrospective study of 2,469 adult patients with single large and huge hepatocellular carcinoma (SLH-HCC) defined as greater than 5.0 cm in diameter who underwent curative resection between January 2005 and December 2015.

Disclosures: The study was supported by the National Science and Technology Major Project of China, the National Natural Science Foundation of China, and the Sun-Yat Sen University Clinical Research 5010 Program. The researchers had no financial conflicts to disclose.

Source: Wang J-C et al.  Eur J Cancer. 2021 Aug 6. doi: 10.1016/j.ejca.2021.07.009.

Key clinical point: Nomograms for both recurrence-free survival and overall survival based on tumor clinical features, operative factors, liver function, and systemic inflammatory or immune status were effective predictors for stratifying SLH-HCC patients in low-, medium-, and high-risk groups.

Major finding: Nomograms for post-surgical recurrence-free survival and overall survival in patients with SLH-HCC achieved C-indexes of 0.85 and 0.86, respectively. The nomograms were based on diameter, differentiation, microvascular invasion, α-fetoprotein, preoperative transcatheter arterial chemoembolisation therapy, scope of liver resection and intraoperative blood transfusion, albumin-bilirubin grade, and neutrophil-to-lymphocyte ratio.

Study details: The data come from a retrospective study of 2,469 adult patients with single large and huge hepatocellular carcinoma (SLH-HCC) defined as greater than 5.0 cm in diameter who underwent curative resection between January 2005 and December 2015.

Disclosures: The study was supported by the National Science and Technology Major Project of China, the National Natural Science Foundation of China, and the Sun-Yat Sen University Clinical Research 5010 Program. The researchers had no financial conflicts to disclose.

Source: Wang J-C et al.  Eur J Cancer. 2021 Aug 6. doi: 10.1016/j.ejca.2021.07.009.

Key clinical point: Approximately half of chronic hepatitis C patients required HCC treatment after a sustained viral response by direct-acting antivirals (DAA).

Major finding: Cumulative 5-year HCC recurrence was 45% and 65%, of hepatitis C patients in curative and palliative treatment groups, respectively. Predictors of early recurrence included AFP greater than 7 ng/mL at 12 weeks after DAA, time from HCC complete response (CR) to DAA initiation of less than 1 year, and the two or more HCC treatments necessary to achieve CR. Predictors of late recurrence included cirrhosis (hazard ratio 1.85), two or more HCC nodules (HR 1.52), and previous palliative HCC treatment (HR 1.71).

Study details: The data come from a retrospective, multicenter cohort study of 365 consecutive adults with chronic hepatitis C who required treatment for HCC after hepatitis C cure via direct-acting antivirals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ogawa E et al. J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659. 

Key clinical point: Approximately half of chronic hepatitis C patients required HCC treatment after a sustained viral response by direct-acting antivirals (DAA).

Major finding: Cumulative 5-year HCC recurrence was 45% and 65%, of hepatitis C patients in curative and palliative treatment groups, respectively. Predictors of early recurrence included AFP greater than 7 ng/mL at 12 weeks after DAA, time from HCC complete response (CR) to DAA initiation of less than 1 year, and the two or more HCC treatments necessary to achieve CR. Predictors of late recurrence included cirrhosis (hazard ratio 1.85), two or more HCC nodules (HR 1.52), and previous palliative HCC treatment (HR 1.71).

Study details: The data come from a retrospective, multicenter cohort study of 365 consecutive adults with chronic hepatitis C who required treatment for HCC after hepatitis C cure via direct-acting antivirals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ogawa E et al. J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659. 

Key clinical point: Approximately half of chronic hepatitis C patients required HCC treatment after a sustained viral response by direct-acting antivirals (DAA).

Major finding: Cumulative 5-year HCC recurrence was 45% and 65%, of hepatitis C patients in curative and palliative treatment groups, respectively. Predictors of early recurrence included AFP greater than 7 ng/mL at 12 weeks after DAA, time from HCC complete response (CR) to DAA initiation of less than 1 year, and the two or more HCC treatments necessary to achieve CR. Predictors of late recurrence included cirrhosis (hazard ratio 1.85), two or more HCC nodules (HR 1.52), and previous palliative HCC treatment (HR 1.71).

Study details: The data come from a retrospective, multicenter cohort study of 365 consecutive adults with chronic hepatitis C who required treatment for HCC after hepatitis C cure via direct-acting antivirals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Ogawa E et al. J Gastroenterol Hepatol. 2021 Aug 9. doi: 10.1111/jgh.15659. 

Key clinical point: Statin use reduced risk of recurrence and improved survival in HCC patients who underwent liver transplants.

Major finding: Hepatocellular carcinoma patients on statins who underwent liver transplants were less likely to experience HCC recurrence (adjusted hazard ratio 0.3), HCC-related mortality (aHR 0.4) and all-cause mortality (aHR 0.3) compared to patients not on statins; a dose-dependent relationship occurred between statin use and HCC recurrence.

Study details: The data come from 430 consecutive HCC patients who underwent liver transplantation between 1995 and 2019; 107 were statin users and 323 were not.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lee HL et al. Liver Transpl. 2021 Aug 9. doi: 10.1002/lt.26258. 

Key clinical point: Statin use reduced risk of recurrence and improved survival in HCC patients who underwent liver transplants.

Major finding: Hepatocellular carcinoma patients on statins who underwent liver transplants were less likely to experience HCC recurrence (adjusted hazard ratio 0.3), HCC-related mortality (aHR 0.4) and all-cause mortality (aHR 0.3) compared to patients not on statins; a dose-dependent relationship occurred between statin use and HCC recurrence.

Study details: The data come from 430 consecutive HCC patients who underwent liver transplantation between 1995 and 2019; 107 were statin users and 323 were not.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lee HL et al. Liver Transpl. 2021 Aug 9. doi: 10.1002/lt.26258. 

Key clinical point: Statin use reduced risk of recurrence and improved survival in HCC patients who underwent liver transplants.

Major finding: Hepatocellular carcinoma patients on statins who underwent liver transplants were less likely to experience HCC recurrence (adjusted hazard ratio 0.3), HCC-related mortality (aHR 0.4) and all-cause mortality (aHR 0.3) compared to patients not on statins; a dose-dependent relationship occurred between statin use and HCC recurrence.

Study details: The data come from 430 consecutive HCC patients who underwent liver transplantation between 1995 and 2019; 107 were statin users and 323 were not.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lee HL et al. Liver Transpl. 2021 Aug 9. doi: 10.1002/lt.26258.